Abstract Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is inevitable. However. it is not entirely clear how ADT fails or how it causes resistance. https://www.soiebiologique.com/limited-price-Test-Evaluation-Command-ACU-Patch-Foliage-Green-flash-choice/